We are pleased to share with you a comprehensive report put together by Dr. Sarah Zaidi for SGH Macro Advisors in which she reviews the main treatment trials for COVID-19 that are currently underway across the globe – Remdesivir, Anti-malarial treatments (chloroquine and hydroxychloroquine), HIV treatments, Ritonavir/lopinavir with interferon beta, and Favipiravir. While, as always, we urge you to read the report in its entirety, we have taken the liberty of highlighting below a very simple but important conclusion of this technical piece, especially in light of recent suggestions that strict “distancing” measures be lifted sooner rather than later for social and economic reasons:
There is no magic bullet for treating COVID-19, but it will not be too long before a promising treatment is available. The use of existing drugs that already have FDA clearance in other diseases and the cooperation between countries to find an effective treatment to stop the spread of the virus spark much needed hope in allaying the panic caused by COVID-19. Results will not be immediate. The first set of results from clinical trials, we expect, should start to come in by early summer. If countries can hold out and manage to flatten the curve of the COVID-19 outbreak in this first wave, then a potential treatment can prevent a much less devastating second wave.
As in the previous COVID reports, SGH has not produced the content of this report, and any edits to the document have been for flow purposes alone. The report is for informational purposes only and does not constitute investment advice.